Cargando…

Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment

A single biomarker is not adequate to identify patients with gastric cancer (GC) who have the potential to benefit from anti-PD-1/PD-L1 therapy, presumably owing to the complexity of the tumour microenvironment. The predictive value of tumour-infiltrating immune cells (TIICs) has not been definitive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yang, Jia, Keren, Sun, Yu, Zhang, Cheng, Li, Yilin, Zhang, Li, Chen, Zifan, Zhang, Jiangdong, Hu, Yajie, Yuan, Jiajia, Zhao, Xingwang, Li, Yanyan, Gong, Jifang, Dong, Bin, Zhang, Xiaotian, Li, Jian, Shen, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388563/ https://www.ncbi.nlm.nih.gov/pubmed/35982052 http://dx.doi.org/10.1038/s41467-022-32570-z

Ejemplares similares

Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2022)

Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2023)

The Association between Blood Indexes and Immune Cell Concentrations in the Primary Tumor Microenvironment Predicting Survival of Immunotherapy in Gastric Cancer
por: Yuan, Jiajia, et al.
Publicado: (2022)

Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer
por: Li, Yilin, et al.
Publicado: (2016)

Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study
por: Xie, Tong, et al.
Publicado: (2020)

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
por: Ji, Zhi, et al.
Publicado: (2019)

Neutrophil extracellular traps induced by the hypoxic microenvironment in gastric cancer augment tumour growth
por: Li, Jiacheng, et al.
Publicado: (2023)

From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression
por: Chen, Zuhua, et al.
Publicado: (2022)

Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer
por: Li, Yilin, et al.
Publicado: (2016)

Knowing the tumour microenvironment to optimise immunotherapy
por: MERLANO, M.C., et al.
Publicado: (2019)

Expression Patterns of Glycosylation Regulators Define Tumor Microenvironment and Immunotherapy in Gastric Cancer
por: Li, Fang, et al.
Publicado: (2022)

Tumor microenvironment and immunotherapy of oral cancer
por: Liu, Chang, et al.
Publicado: (2022)

Current status, challenges and perspectives: immunotherapy and tumour microenvironment in thoracic cancer
por: Luo, Peng, et al.
Publicado: (2020)

Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor
por: Chen, Yang, et al.
Publicado: (2021)

Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer
por: Li, Yilin, et al.
Publicado: (2014)

Roles of circRNAs in the tumour microenvironment
por: Zhang, Qiuge, et al.
Publicado: (2020)

Immune gene patterns and characterization of the tumor immune microenvironment associated with cancer immunotherapy efficacy
por: Lin, Lili, et al.
Publicado: (2023)

Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma
por: Chen, Yujia, et al.
Publicado: (2023)

Use of Radiomics to Predict Response to Immunotherapy of Malignant Tumors of the Digestive System
por: Ji, Zhi, et al.
Publicado: (2020)

Immunotherapy of targeting MDSCs in tumor microenvironment
por: Sui, Hongshu, et al.
Publicado: (2022)

Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target
por: Li, Jiaxin, et al.
Publicado: (2023)

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
por: Wang, Zhenghang, et al.
Publicado: (2022)

Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses
por: Deng, Ruiyi, et al.
Publicado: (2022)

Identifying tumour microenvironment-related signature that correlates with prognosis and immunotherapy response in breast cancer
por: Zhao, Hongying, et al.
Publicado: (2023)

Identification and validation of immunotherapy for four novel clusters of colorectal cancer based on the tumor microenvironment
por: Zheng, Xiaoyong, et al.
Publicado: (2022)

Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses
por: Chen, Yu-Pei, et al.
Publicado: (2021)

Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations
por: Colton, Madyson, et al.
Publicado: (2020)

Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses
por: Oliver, Amanda J., et al.
Publicado: (2020)

A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
por: Jiao, Xi, et al.
Publicado: (2021)

Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer
por: Lin, Yilin, et al.
Publicado: (2023)

Tumour microenvironment landscape and immunotherapy response in bladder cancer decoded by stromal MOXD1 based on copper-related genes signature
por: Wang, Wenhao, et al.
Publicado: (2022)

Lysosome blockade induces divergent metabolic programs in macrophages and tumours for cancer immunotherapy
por: Ma, Jing, et al.
Publicado: (2023)

CT-based delta radiomics in predicting the prognosis of stage IV gastric cancer to immune checkpoint inhibitors
por: Li, Jiazheng, et al.
Publicado: (2023)

Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites
por: Kou, Furong, et al.
Publicado: (2021)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
por: Qi, Changsong, et al.
Publicado: (2023)

Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy
por: Zhang, Yalei, et al.
Publicado: (2021)

Neuromedin U and neurotensin may promote the development of the tumour microenvironment in neuroblastoma
por: Yang, Daheng, et al.
Publicado: (2021)

Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities
por: Linares, Christian A., et al.
Publicado: (2023)

The immunosuppressive microenvironment and immunotherapy in human glioblastoma
por: Zhang, Xuehua, et al.
Publicado: (2022)

Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy
por: Feng, Hai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nuh8m8gvb2g86t5b8pgp405925